The Future of Life Sciences: Trends and Opportunities
Trends — The life sciences market is constantly evolving, with technological, regulatory, and economic pressures driving everchanging trends. At ALTEN, these changes continually prompt further developments in a sector where every day counts for patients.
QUENTIN BIROT /
DIRECTOR OF LIFE SCIENCES MANUFACTURING & CLINICAL OPERATIONS – ALTEN
What are the biggest current trends & stakes within the life sciences market?
— The life sciences market is evolving rapidly, coping with constant technological, regulatory, and socio-economic changes. The rise of pressures, R&D costs, and ESG compliance, pushes for innovative strategies to maintain vigorous development while optimising expenses. Consequently, outsourcing to Clinical Research Organisations (CROs) and Contract Development Manufacturing Organisations (CDMOs) is increasingly vital for balancing cost-efficiency with high-quality, innovative outputs. Furthermore, the pandemic exposed supply chain vulnerabilities, prompting Pharma reshoring for resilience, while balancing Medtech’s need for global efficiency. AI also revolutionises trials and manufacturing, while blockchain supports data integrity, requiring solid implementation and regulatory adaptation. These advancements facilitate the merging of MedTech and Pharma, which fosters innovative therapies and diagnostics. This convergence enhances patient care and requires integrated technologies and harmonised regulations.
What is ALTEN’s perspective?
— ALTEN applies a multidimensional approach to address these trends. In response to economic pressures, Aixial’s CRO comprehensive services enhance R&D efficiency, containing costs without sacrificing innovation or quality. Additionally, ALTEN aligns client operations with global ESG standards, boosting compliance and competitiveness. Furthermore, we are well-positioned to address the challenges posed by supply chain vulnerabilities. With a presence in over 30 countries, ALTEN’s local embedding near manufacturing and R&Dclusters ensures a balance between local production and global operational efficiencies. In terms of digitalisation, ALTEN, together with SDG and Lincoln, uses AI to optimise trials and manufacturing, reducing time to market and improving quality. We ensure secure and transparent data management, leveraging ALCOA+ and blockchain. To address the MedTech and Pharma convergence, ALTEN leverages its engineering roots and strong life sciences expertise to drive innovation at this intersection. Through Aixial, ALTEN enhances patient care with advanced therapies and diagnostics, integrating both fields.
What is our Group’s added value?
— ALTEN’s added value lies in our comprehensive and tailored approach to meet client needs. We deliver services spanning the entire product lifecycle, from early R&D to regulatory compliance and market release, which ensure seamless project progression. This is complemented by ALTEN’s unique glocal synergy. Our global expertise, enhanced by local execution, effectively meets diverse regulatory and market demands. Central to these capabilities is our integrated technical direction, supported by a sturdy delivery framework and centres of excellence. This combination provides tailored solutions and guarantees high-quality standards.
